Sana Biotechnology Inc (SANA) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Sana Biotechnology Inc stock $1.73, price $1.88, that is 8.0% below the price, quality 26 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Sana Biotechnology Inc
SANA · USThe stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.
How to read this chart
60‑month range $1.34 – $25.88 · fair‑value band $1.30 – $2.17 · the $1.88 price screens above the $1.73 fair value. As of Nov 11, 2026.
Every Wednesday you see whether Sana Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
Show moreShow less
It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases.
The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.
The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018.
Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Stock analysis
Sana Biotechnology Inc (SANA) currently trades at $1.88, while our estimate is $1.73, so the stock looks roughly fairly valued today (gap 8.7%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $1.30 (bear) to $2.17 (bull), the price of $1.88 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Sana Biotechnology Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$244M in FY2025.
Key figures
Market cap $571M Small · EPS (TTM) $−0.5200 · Return on equity −79.5% · Return on assets (EBIT) −43.4% (5-year average) · Free cash flow −$145M · Net debt $7.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).
What moves the price
The share trades about 64% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −8%, SANA screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Watch SANA, get fair value alerts →
Compare Sana Biotechnology Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EBIT margin by industry
- P/S ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs SANA |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs SANA |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs SANA |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs SANA |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs SANA |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs SANA |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs SANA |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs SANA |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs SANA |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs SANA |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Sana Biotechnology Inc (SANA) overvalued or undervalued?
What is the fair value of SANA?
What is the quality score of SANA?
What is the price target for Sana Biotechnology Inc (SANA)?
What is the Sana Biotechnology Inc stock forecast for 2026?
What is the intrinsic value of Sana Biotechnology Inc (SANA)?
Is Sana Biotechnology Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of SANA?
How much is Sana Biotechnology Inc worth?
What do the bullish and bearish scenarios say about SANA?
How solid is the balance sheet of Sana Biotechnology Inc (SANA)?
How far is SANA from its 52-week high?
Which stocks are comparable to Sana Biotechnology Inc?
Is Sana Biotechnology Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Sana Biotechnology Inc (SANA)?
What should I pay attention to with Sana Biotechnology Inc right now?
Key figures of Sana Biotechnology Inc
How large is the market capitalisation of Sana Biotechnology Inc (SANA)?
What are the earnings per share of Sana Biotechnology Inc (SANA)?
What is the return on equity of Sana Biotechnology Inc (SANA)?
What is the EBIT return on assets of Sana Biotechnology Inc (SANA)?
How much free cash flow does Sana Biotechnology Inc (SANA) generate?
How much net debt does Sana Biotechnology Inc (SANA) carry?
Watch Sana Biotechnology Inc in the live analysis
One click puts Sana Biotechnology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.